Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,186actual
Sites
175
Countries
Brazil, Bulgaria, China +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-01 | actual | When the study began enrolling |
| Primary completion | 2021-03-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2017-05-23 | actual | When this record first appeared on the registry |
| Results posted | 2022-04-07 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer NSCLC
Interventions
- Drug: Durvalumab
- Drug: Tremelimumab
- Drug: Abraxane + carboplatin
- Drug: Gemcitabine + cisplatin
- Drug: Gemcitabine + carboplatin
- Drug: Pemetrexed + carboplatin
- Drug: Pemetrexed + cisplatin
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS); D + SoC Compared With SoC Alone
measured Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Overall Survival (OS); D + SoC Compared With SoC Alone
measured From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-07-09 · 2.0 MB · Prot_002.pdf
Statistical Analysis Planposted 2021-02-25 · 863 KB · SAP_003.pdf
Publications
- PMID 39243945 — linked by the registry
- PMID 37777827 — linked by the registry
- PMID 36327426 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed